Sélectionner la langue
Integrin alpha V beta 6
Integrin alpha V beta 6 Informations sur la molécule
| Nom anglais | Integrin alpha-V/beta-6 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 6 | Alias de la cible | |
| Phase de R&D la plus avancée | Phase 2 Clinical | ||
| Nom anglais | Integrin alpha-V/beta-6 |
| Alias de la cible | |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 6 |
| Phase de R&D la plus avancée | Phase 2 Clinical |
Integrin alpha V beta 6 Liste de produits
- Attribut
Protein (8)Cell (2)Kits (1)
- Bibliothèque de produits
En ligne (11)
- Espèces
Human (5)Mouse (2)Cynomolgus (2)Rat (1)Mouse & Human (1)
- Étiquette
His Tag (5)His Tag & Avi Tag (3)- (3)
- Marqueur
Unconjugated (5)Biotin-labeled (3)- (3)
Ajouter au panier
Quantité totale11
- 1
- 2
Integrin alpha V beta 6Contexte de la molécule
Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| IDL-2965 | IDL-2965 | Phase 2 Clinical | Indalo Therapeutics Inc | Idiopathic Pulmonary Fibrosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Bexotegrast | PLN-74809 | Phase 2 Clinical | Pliant Therapeutics Inc | Cholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Respiratory Distress Syndrome, Adult | Details |
| Nesvategrast | SF-0166; OTT-166(OcuTerra Therapeutics) | Phase 2 Clinical | OcuTerra Therapeutics Inc, Scifluor Life Sciences Inc | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration | Details |
| 18F-αvβ6-Binding-Peptide | 18F-αvβ6-BP | Phase 1 Clinical | National Cancer Institute, National Institutes Of Health | Breast Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Lung Neoplasms; Metastatic breast cancer; Pancreatic Neoplasms; Rectal Neoplasms | Details |
| [18F]FP-R01-MG | [18F]FP-R01-MG-F2; [18F]FP-R01-MG | Phase 1 Clinical | Chinese Academy Of Medical Science & Peking Union Medical College, Pliant Therapeutics Inc, Stanford University | Brain metastases; Carcinoma, Non-Small-Cell Lung; Cholangitis, Sclerosing; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Pancreatic Neoplasms | Details |
| Ga-68-Trivehexin | RAD-301 | Phase 1 Clinical | Trimt GmbH | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | Details |
Avis sur les produits
A***l2022-03-15
0Mettre un likeGreat communication from the Acro team--quickly received an email detailing the estimated delivery timeframe and asking if that timeframe was acceptable. Product was ready per the timeline provided by the Acro biosystems team and shipped. This was a new product for us (though we’ve used other acro biosystems products previously) and worked well for our intended use with Surface Plasmon Resonance (SPR). Thank you all!
- Informations sur la molécule
- Liste de produits
- Avis sur les produits
- Informations sur les médicaments cliniques
Partager vers :